期刊文献+

培美曲塞单药治疗晚期非小细胞肺癌复治患者的临床观察 被引量:9

Pemetrexed alone regimen in treatment of advanced chemo-recurrent non-small cell lung cancer
原文传递
导出
摘要 为了探讨培美曲塞单药治疗晚期复治非小细胞肺癌(NSCLC)的疗效及不良反应,经病理学或细胞学确诊的复发性晚期NSCLC患者58例,给予培美曲塞500mg/m2,d1,静脉滴入,每3周重复,2~3个周期后评价疗效及不良反应。58例患者中无完全缓解病例,部分缓解(PR)6例,稳定(SD)33例,进展19(PD)例,疾病控制率67.2%(39/58)。中位无疾病进展时间(MPFS)2.9个月。主要不良反应为粒细胞下降、贫血。初步研究结果提示,培美曲塞单药治疗一线化疗失败的晚期NCLC患者疗效确切。不良反应发生率低,耐受性较好。 The objective of this study was to evaluate the efficacy and side effects of pemetrexed alone in the treatment of advanced chemo-recurrent NSCLC.Fifty-eight patients with advanced NSCLC who had failed to previous chemotherapy were enrolled in this study and all of these patients had been confirmed with pathology or cytology.The patients received pemetrexed 500 mg/m2 on day 1,by intravenous infusion,with every 21 days,and 21 days as one cycle.All the patients who received 2 or 3 cycles were evaluated.There was no case with complete response.Six cases had partial response,33 cases had stable disease and 19 cases had progressive disease.The disease control rate was 67.2%(39/58).The median survival time was 2.9 months.The common adverse effects were leucopenia and anemia.Pemetrexed is effective and feasible for advanced recurrent NSCLC.Pemetrexed is one of the choices for NSCLC patients who fail in the first line chemotherapy.
出处 《中华肿瘤防治杂志》 CAS 2010年第20期1679-1680,共2页 Chinese Journal of Cancer Prevention and Treatment
关键词 培美曲塞 非小细胞肺 药物疗法 治疗结果 pemetrexed carcinoma non-small cell lung drug therapy treatment outcome
  • 相关文献

参考文献3

二级参考文献21

  • 1Schiller JH, Harrington D. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer [ J ] . N Engl J Med, 2002, 346: 92-98.
  • 2Calvert H. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents [ J ] . Semi Oncol, 1999, 26 ( Supp 1) : 3-10.
  • 3Nicholas J. Vogelzang, James J. Phase Ⅲ study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma [ J ] .J Clin Oncol, 2003,21:2636-2644.
  • 4Rusthoven J, Eisenhaucr E, Butts C, et al. Muhitargeted antifolate LY231514 as first line chemotherapy for patients with advanced non-small cell lung cancer: a phase Ⅱ study [ J ] . J Clin Oncol, 1999, 17: 1194-1199.
  • 5Clarke S J, Abratt R, Goedhals L, et al. Phase Ⅱ trial of pemetrexed disodium in chemotherapy-naive patients with advanced non-small cell lung cancer [ J ] . Ann Oncol, 2002, 13: 737-741.
  • 6Ceppi P, Volante M, Saviozzi S, et al: Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase [ J ] . Cancer,2006, 107: 1589-1596.
  • 7Hanna N, Frances A. Shepherd, Frank V. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy [ J ] .J Clin Oncol, 2004, 22: 1589-1597.
  • 8Scaglioti G, Parikh P, yon Pawel J, et al. Phase m study comparing cisplatin plus gemcitatine with cisplatin plus pemetrexed in chemotherapy:naive patients with advanced-stage non-small cell lung cancer [ J ] . J Clin Oncol, 2008, 26:3543-3551.
  • 9Sigmond J, Backus HH, Wouters D, et al. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression [ J ] . Biochem Pharmacol,2003,66:431-438.
  • 10Giovannetti E, Mey V, Nannizzi S, et al.Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small cell lung cancer ceils [ J ] . Mol Pharmacol,2005, 68:110-118.

共引文献42

同被引文献67

引证文献9

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部